EPO and acute myeloid leukemia: Results showed that IL-27 treatment caused a dose-dependent increase in cell proliferation of 4 leukemic cell lines, including the AML cell line, OCI-AML5, and the erythroleukemic cell lines, TF-1, UT-7, and UT-7/EPO (Fig. 2A).